INGELHEIM, Germany--(BUSINESS WIRE)--For media outside of the U.S., the UK & Canada only. Boehringer Ingelheim today announces a new study of Pradaxa® (dabigatran etexilate) in patients with atrial fibrillation (AF). The RE-CIRCUIT™ study will investigate the safety and efficacy of uninterrupted anticoagulant treatment with Pradaxa® in patients with AF who undergo ablation.5 Results of the study are expected in 2016.
Help employers find you! Check out all the jobs and post your resume.
